XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Investments - Schedule of Valuation Methodology and Unobservable Inputs for Level 3 Assets and Liabilities Measured at Fair Value (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Spinal Kinetics [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Contingent consideration estimated fair value   $ 17,200
Decrease in fair value recognized in acquisition-related amortization and remeasurement   (16,214)
Contingent consideration estimated fair value at June 30   $ 986
Lattus Spine [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Consideration transferred $ 9,900  
Counterparty discount rate 9.00%  
Revenue risk-adjusted discount rate 6.50%  
Lattus Spine [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Contingent consideration estimated fair value $ 11,200  
Decrease in fair value recognized in acquisition-related amortization and remeasurement (1,300)  
Contingent consideration estimated fair value at June 30 9,900  
Neo Medical [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Neo Medical Convertible Loan $ 7,690  
Fair value discount rate 18.00%  
Estimated equity volatility 74.10%